Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
Saved in:
| Title: | Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis. |
|---|---|
| Authors: | Wilson JM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Dage JL; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA., Qian HR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Irelan CL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Crowder HS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Duffin KL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Mintun M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Brooks DA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Gerstein HC; Population Health Research Institute, Hamilton, Ontario, Canada., Bethel MA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA. |
| Source: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2026 Apr; Vol. 22 (4), pp. e71391. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.71391 |
